Health Care · S&P 500
Regeneron Pharmaceuticals
Regeneron is a large US biopharma company developing drugs such as the eye treatment Eylea and immuno-oncology therapies. S&P 500 constituent. Sector: Health Care (Biotechnology). Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.
REGN Updated Jul 11, 2026 2 AI consumers
Annual return · 2026-07-10'21+30.7%'22+14.2%'23+21.7%'24-18.9%'25+9%YTD-13.7%
Money in ▸·
Regeneron Pharmaceuticalsapprox. $14.2B
▸ Money out·
Financials & Segments
- Total revenue · approx. $14.2B (FY2024)
- Segments · Net Product Sales · Collaboration Revenue
Revenue from
No refined links yet.
Pays to
No refined links yet.